GLP-1 based drugs are transforming the treatment of obesity and opening up new avenues for addressing heart disease, ...

“I don’t see [GLP-1s] as this panacea,” Stanford said. “I see them as a very useful tool among other tools to treat patients with obesity ... who was in a tragic car accident.

Biolexis Therapeutics Inc. has announced findings from a study of its oral small-molecule GLP-1 agonist, BLX-7006, in a ...

As appetite suppressants, GLP-1s have also increasingly been used to treat obesity and facilitate weight loss. Two of the most common are Novo Nordisk’s Ozempic, for Type 2 diabetes, and Wegovy ...

These new challengers are anticipated to account for roughly $70 billion of the total GLP-1 market, which is expected to be worth $200 billion by 2031. Our report on the obesity drug market ...

Opens in a new tab or window Recently, GLP-1 receptor agonist medications ... coverage with these medications for the treatment of obesity could be challenging, but we did not know how this ...

Amid an ongoing debate over what role, if any, GLP-1 medications should play in treating children who are still in elementary ...

Three scientists are honoured for developing a class of blockbuster weight-loss drugs. Is a Nobel prize on the way?

“GLP-1 serves multiple key functions in the body,” explains Christopher McGowan, M.D., a gastroenterologist specializing in obesity medicine and endobariatrics, and founder of True You Weight ...

Whether positive or negative, your mood may feel different on GLP-1 medications. Researchers share why that might be and how ...

Women who take Wegovy to treat obesity have the greatest likelihood ... The researchers only studied two types of drugs that mimic the GLP-1 hormone to make people feel fuller for longer ...